Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication
US policymakers and payers should consider indication-based pricing in a bid to cut down on higher cancer drug costs in the US, according to research …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
